Background: AML is a common hematopoietic malignancy. Several consolidation chemotherapy protocols have been introduced for treatment of AML, including IDAC protocol. Purpose: To assess the effectiveness of the IDAC protocol for consolidation treatment of AML patients. Patients and methods: Study was carried out on 56 AML patients treated in NIHBT from 9/2010 to 11/2012. Results: (1) Complete remission rate was 80.4 percent ; partial remission rate was 10.7 percent ; no remission - 8.9 percent ; (2) Infection has been seen in 100 percent patients, and most common infectious locations were oral cavity (32.1 percent ); respiratory tract (17.9 percent ); and sepsis (16.1 percent ). 5 most common infectious agents were E. coli, Klebshiella pneumonia, Pseudomonas aeruginosa, fungi Candida and Aspergillus; (3) Lowest neutrophil count was 0.3 + or - 0.2 G/L; lowest platelet counts was 21 + or - 15 G/I; (4) Hematological adverse effects: Neutropenia and thrombocytopenia have been seen in 100 percent patients, from which neutropenia grades 2-3 have been observed in 21.4 percent and 60.7 percent patients, respectively; and thrombocytopenia grades 2-3 - 28.5 percent and 53.6 percent, respectively). Conclusion: IDAC is an effective chemotherapy protocol for consolidation treatment of AML patients.
- Đăng nhập để gửi ý kiến